Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825822 | 0.88 | EPHX2 (0.43) | LMNAKDM4ERXFP1EPHX2 | |
| SCHEMBL16825726 | 0.82 | LMNA (0.52) | LMNAKDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL18135562 | 0.80 | LMNA (0.63) | LMNAKDM4EPOLBMAPTRET | |
| SCHEMBL18135561 | 0.79 | POLB (0.60) | LMNAPOLBMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16825929 | 0.79 | KDM4E (0.57) | LMNAKDM4EMAPTHPGDGAA | |
| SCHEMBL16826017 | 0.78 | KDM4E (0.46) | LMNAKDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL16825684 | 0.78 | KDM4E (0.61) | LMNAKDM4EPOLBMAPTHSD17B10 | |
| SCHEMBL16825942 | 0.78 | POLB (0.63) | LMNAPOLBMAPTHPGDALDH1A1 | |
| SCHEMBL16826434 | 0.77 | MAPT (0.59) | LMNAKDM4EPOLBMAPTHPGD | |
| SCHEMBL18135566 | 0.77 | TSHR (0.52) | LMNAMAPTRXFP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | LMNA 3856/4885KDM4E 2405/4885POLB 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.